Woroń , J. (2020) “SGLT2 inhibitors – why a synthesis of empagliflozin is a significant progression in diabetes pharmacotherapy?”, Medycyna Faktow (J EBM), 13(2(47), pp. 147-150. doi: 10.24292/01.MF.0220.2.